VERAXA Biotech to Showcase BiTAC Cancer Platforms at BIO International Convention

VERAXA Biotech AG (NASDAQ: VRXA) is set to highlight partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms at the upcoming BIO International Convention, scheduled for June 22-25 in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.

According to the company, the findings, together with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention.

The BiTAC platforms represent VERAXA’s approach to next-generation antibody-based therapeutics. The BiTAC-ADC platform leverages bispecific antibodies to deliver cytotoxic agents directly to tumor cells, while the BiTAC-TCE platform engages T cells to attack cancer cells. Both aim to address limitations of conventional therapies by enhancing specificity and reducing side effects.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. The company’s pipeline includes bispecific T cell engagers, bispecific ADCs, and other innovative formats, guided by quality-by-design principles.

The BIO International Convention is a key event for biotech companies to showcase their technologies and forge partnerships. VERAXA’s participation underscores its commitment to advancing its platforms toward clinical development. The company’s latest data could attract interest from potential collaborators seeking to expand their oncology pipelines.

For more information, the press release is available at https://ibn.fm/r8zEz. Updates on VERAXA can be found in the company’s newsroom at http://ibn.fm/VRXA.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is VERAXA Biotech to Showcase BiTAC Cancer Platforms at BIO International Convention.

The post VERAXA Biotech to Showcase BiTAC Cancer Platforms at BIO International Convention appeared first on citybuzz.